Metabolomic profiling of the Malaria Box reveals antimalarial target pathways

Erik L. Allman, Heather J. Painter, Jasmeet Samra, Manuela Carrasquilla, Manuel Llinás

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The threat of widespread drug resistance to frontline antimalarials has renewed the urgency for identifying inexpensive chemotherapeutic compounds that are effective against Plasmodium falciparum, the parasite species responsible for the greatest number of malaria-related deaths worldwide. To aid in the fight against malaria, a recent extensive screening campaign has generated thousands of lead compounds with low micromolar activity against blood stage parasites. A subset of these leads has been compiled by the Medicines for Malaria Venture (MMV) into a collection of structurally diverse compounds known as theMMVMalaria Box. Currently, little is known regarding the activity of these Malaria Box compounds on parasite metabolism during intraerythrocytic development, and a majority of the targets for these drugs have yet to be defined. Here we interrogated the in vitro metabolic effects of 189 drugs (including 169 of the drug-like compounds from the Malaria Box) using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). The resulting metabolic fingerprints provide information on the parasite biochemical pathways affected by pharmacologic intervention and offer a critical blueprint for selecting and advancing lead compounds as next-generation antimalarial drugs. Our results reveal several major classes of metabolic disruption, which allow us to predict the mode of action (MoA) for many of the Malaria Box compounds. We anticipate that future combination therapies will be greatly informed by these results, allowing for the selection of appropriate drug combinations that simultaneously target multiple metabolic pathways, with the aim of eliminating malaria and forestalling the expansion of drug-resistant parasites in the field.

Original languageEnglish (US)
Pages (from-to)6635-6643
Number of pages9
JournalAntimicrobial agents and chemotherapy
Volume60
Issue number11
DOIs
StatePublished - Nov 2016

Fingerprint

Metabolomics
Antimalarials
Malaria
Parasites
Pharmaceutical Preparations
Dermatoglyphics
Drug Combinations
Plasmodium falciparum
Metabolic Networks and Pathways
Drug Resistance
Mass Spectrometry
High Pressure Liquid Chromatography

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Allman, Erik L. ; Painter, Heather J. ; Samra, Jasmeet ; Carrasquilla, Manuela ; Llinás, Manuel. / Metabolomic profiling of the Malaria Box reveals antimalarial target pathways. In: Antimicrobial agents and chemotherapy. 2016 ; Vol. 60, No. 11. pp. 6635-6643.
@article{8a0b84e176094c88985813c3b3fda398,
title = "Metabolomic profiling of the Malaria Box reveals antimalarial target pathways",
abstract = "The threat of widespread drug resistance to frontline antimalarials has renewed the urgency for identifying inexpensive chemotherapeutic compounds that are effective against Plasmodium falciparum, the parasite species responsible for the greatest number of malaria-related deaths worldwide. To aid in the fight against malaria, a recent extensive screening campaign has generated thousands of lead compounds with low micromolar activity against blood stage parasites. A subset of these leads has been compiled by the Medicines for Malaria Venture (MMV) into a collection of structurally diverse compounds known as theMMVMalaria Box. Currently, little is known regarding the activity of these Malaria Box compounds on parasite metabolism during intraerythrocytic development, and a majority of the targets for these drugs have yet to be defined. Here we interrogated the in vitro metabolic effects of 189 drugs (including 169 of the drug-like compounds from the Malaria Box) using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). The resulting metabolic fingerprints provide information on the parasite biochemical pathways affected by pharmacologic intervention and offer a critical blueprint for selecting and advancing lead compounds as next-generation antimalarial drugs. Our results reveal several major classes of metabolic disruption, which allow us to predict the mode of action (MoA) for many of the Malaria Box compounds. We anticipate that future combination therapies will be greatly informed by these results, allowing for the selection of appropriate drug combinations that simultaneously target multiple metabolic pathways, with the aim of eliminating malaria and forestalling the expansion of drug-resistant parasites in the field.",
author = "Allman, {Erik L.} and Painter, {Heather J.} and Jasmeet Samra and Manuela Carrasquilla and Manuel Llin{\'a}s",
year = "2016",
month = "11",
doi = "10.1128/AAC.01226-16",
language = "English (US)",
volume = "60",
pages = "6635--6643",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

Metabolomic profiling of the Malaria Box reveals antimalarial target pathways. / Allman, Erik L.; Painter, Heather J.; Samra, Jasmeet; Carrasquilla, Manuela; Llinás, Manuel.

In: Antimicrobial agents and chemotherapy, Vol. 60, No. 11, 11.2016, p. 6635-6643.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metabolomic profiling of the Malaria Box reveals antimalarial target pathways

AU - Allman, Erik L.

AU - Painter, Heather J.

AU - Samra, Jasmeet

AU - Carrasquilla, Manuela

AU - Llinás, Manuel

PY - 2016/11

Y1 - 2016/11

N2 - The threat of widespread drug resistance to frontline antimalarials has renewed the urgency for identifying inexpensive chemotherapeutic compounds that are effective against Plasmodium falciparum, the parasite species responsible for the greatest number of malaria-related deaths worldwide. To aid in the fight against malaria, a recent extensive screening campaign has generated thousands of lead compounds with low micromolar activity against blood stage parasites. A subset of these leads has been compiled by the Medicines for Malaria Venture (MMV) into a collection of structurally diverse compounds known as theMMVMalaria Box. Currently, little is known regarding the activity of these Malaria Box compounds on parasite metabolism during intraerythrocytic development, and a majority of the targets for these drugs have yet to be defined. Here we interrogated the in vitro metabolic effects of 189 drugs (including 169 of the drug-like compounds from the Malaria Box) using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). The resulting metabolic fingerprints provide information on the parasite biochemical pathways affected by pharmacologic intervention and offer a critical blueprint for selecting and advancing lead compounds as next-generation antimalarial drugs. Our results reveal several major classes of metabolic disruption, which allow us to predict the mode of action (MoA) for many of the Malaria Box compounds. We anticipate that future combination therapies will be greatly informed by these results, allowing for the selection of appropriate drug combinations that simultaneously target multiple metabolic pathways, with the aim of eliminating malaria and forestalling the expansion of drug-resistant parasites in the field.

AB - The threat of widespread drug resistance to frontline antimalarials has renewed the urgency for identifying inexpensive chemotherapeutic compounds that are effective against Plasmodium falciparum, the parasite species responsible for the greatest number of malaria-related deaths worldwide. To aid in the fight against malaria, a recent extensive screening campaign has generated thousands of lead compounds with low micromolar activity against blood stage parasites. A subset of these leads has been compiled by the Medicines for Malaria Venture (MMV) into a collection of structurally diverse compounds known as theMMVMalaria Box. Currently, little is known regarding the activity of these Malaria Box compounds on parasite metabolism during intraerythrocytic development, and a majority of the targets for these drugs have yet to be defined. Here we interrogated the in vitro metabolic effects of 189 drugs (including 169 of the drug-like compounds from the Malaria Box) using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). The resulting metabolic fingerprints provide information on the parasite biochemical pathways affected by pharmacologic intervention and offer a critical blueprint for selecting and advancing lead compounds as next-generation antimalarial drugs. Our results reveal several major classes of metabolic disruption, which allow us to predict the mode of action (MoA) for many of the Malaria Box compounds. We anticipate that future combination therapies will be greatly informed by these results, allowing for the selection of appropriate drug combinations that simultaneously target multiple metabolic pathways, with the aim of eliminating malaria and forestalling the expansion of drug-resistant parasites in the field.

UR - http://www.scopus.com/inward/record.url?scp=84994796512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994796512&partnerID=8YFLogxK

U2 - 10.1128/AAC.01226-16

DO - 10.1128/AAC.01226-16

M3 - Article

C2 - 27572391

AN - SCOPUS:84994796512

VL - 60

SP - 6635

EP - 6643

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -